Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Culturally tailored ADA meals for Asian Indian and Filipino adults with type 2 diabetes

Official title: Validation of NOURISH Project's Culturally Tailored Meals on Postprandial Glycemic Response Using Continuous Glucose Monitoring: A Quantitative and Qualitative Study

Run by Stanford University · NCT06836479 · Data updated 2026-11-12

This project will test whether culturally tailored, American Diabetes Association–compliant meals improve blood sugar control in Asian Indian and Filipino adults with type 2 diabetes by using a continuous glucose monitor.

More Type 2 Diabetes trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment30 (estimated)
SponsorStanford University
Academic / other
Locations1 site (Stanford, California)
StatusRecruiting
StartedAugust 31, 2026
Main results expectedFebruary 2027
Study endsApril 2027
Registry record updatedSeptember 28, 2026
Trial IDNCT06836479 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with type 2 diabetes who self-identify as Asian Indian or Filipino, are not taking insulin, GLP-1 receptor agonists, or SGLT2 inhibitors, can pick up meals at Stanford, and are willing to wear a CGM for 30 days.

Probably not a fit

People using insulin, GLP-1 or SGLT2 drugs, those with severe food allergies or intolerances that prevent eating the provided meals, or anyone unable to pick up meals at Stanford or complete the protocol are unlikely to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This crossover intervention compares each participant's usual self-selected diet with a period of receiving NOURISH culturally tailored, ADA-compliant meals. Adults who self-identify as Asian Indian or Filipino and have type 2 diabetes will wear a continuous glucose monitor for roughly 30 days and keep a food log via Tastermonial. NOURISH meals are delivered to designated pick-up points on the Stanford campus and clinics, and participants alternate between control and intervention phases for within-person comparisons. Investigators will analyze CGM metrics such as postprandial glucose excursions and time-in-range to quantify dietary effects.

Why it matters

Potential benefit: If successful, this approach could reduce post-meal glucose spikes and increase time-in-range for Asian Indian and Filipino adults with type 2 diabetes.

How similar studies have gone: Prior work using medically tailored or culturally adapted meals with CGM monitoring has shown modest glycemic improvements, but evidence specifically in Asian Indian and Filipino populations is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Self-identification as Asian Indian or Filipino
* Diagnosed with T2DM
* Pick up and consume personally tailored cultural food and meal options for 1 week
* Willing to wear a CGM for 30 days

Exclusion Criteria:

* Currently taking insulin
* Known severe allergic reactions and/or food intolerances that would interfere with the ability to eat
* Those who, in the opinion of the investigators, cannot reliably complete the study protocol.

Where it's running

  • Stanford University
    Stanford, California, United States
    Recruiting

Study contacts

  • Principal investigator: Minal Moharir, MD — Stanford University

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.